Treatment with ibrutinib (IBR), an inhibitor of Bruton’s tyrosine kinase (BTK), is known to expel CLL cells from the protective LN in a subset of patients (7–9). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.